Pyxis Oncology (PYXS) Net Margin (2024 - 2025)

Pyxis Oncology (PYXS) posted quarterly Net Margin of 166.6% for Q4 2025, up 74.4% quarter-over-quarter from 650.85% in Q2 2025.

Pyxis Oncology (PYXS) Net Margin (2024 - 2025) Analysis & Trends

Pyxis Oncology (PYXS) has reported Net Margin for 2 consecutive years, with 166.6% the latest figure, recorded in Q4 2025.

In Q4 2025, Net Margin changed N/A year-over-year to 166.6%; the TTM figure through Dec 2025 stood at 586.69% (down 5524.0% YoY), while the FY2025 annual figure was 574.55%, down 9560.0% from the prior year.
Net Margin improved to 166.6% in Q4 2025 per PYXS's latest filing, from 650.85% in the prior quarter.
Across five years, Net Margin topped out at 72.66% in Q1 2024 and bottomed at 650.85% in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Margin (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	32.99%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	30.23%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	31.16%
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-539.31%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	13.90%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	12.74%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-3.12%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	12.09%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-16.51%
10	Pyxis Oncology	199.01 Mn	166.02 Mn	-	-

Download Data